Drugs / SCB-2023
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05926440 | Aug 2023 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-2023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05926440 ↗ |
| Modality | Vaccine | “recombinant SARS-CoV-2 trimeric S-protein subunit vaccine” NCT05926440 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05926440 ↗ |